Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Various driver gene mutations have been identified in lung cancer. Among them, human
epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung
cancers. Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2
receptors. This is a prospective, single-arm, open-label phase II study, designed to evaluate
the efficacy and safety of pyrotinib combined with thalidomide in advanced non-small-cell
lung cancer patients with HER2 exon 20 insertions.